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Abstract: Mycobacterial infections are considered to a serious challenge of medicine, and
the emergence of MDR and XDR tuberculosis is a serious public health problem.
Tuberculosis can cause high morbidity and mortality around the world, particularly in
developing countries. The emergence of drug-resistant Mycobacterium infection following
limited therapeutic technologies coupled with the serious worldwide tuberculosis epidemic
has adversely affected control programs, thus necessitating the study of the role bacterio-
phages in the treatment of mycobacterial infection. Bacteriophages are viruses that are
isolated from several ecological specimens and do not exert adverse effects on patients.
Phage therapy can be considered as a signiﬁcant alternative to antibiotics for treating MDR
and XDR mycobacterial infections. The useful ability of bacteriophages to kill
Mycobacterium spp has been explored by numerous research studies that have attempted
to investigate the phage therapy as a novel therapeutic/diagnosis approach to mycobacterial
infections. However, there are restricted data about phage therapy for treating mycobacterial
infections. This review presents comprehensive data about phage therapy in the treatment of
mycobacterial infection, speciﬁcally tuberculosis disease.
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Introduction
Mycobacterium species (spp) can create a variety of infections such as tuberculosis
(TB), Searls ulcer, leprosy, and ﬁsh tank granuloma.1 TB, caused by
Mycobacterium tuberculosis (Mtb), is one of the most serious public health pro-
blems that can cause high morbidity and mortality worldwide.2–4 Based on WHO
TB report in 2018, TB remained to be a major global health challenge and, in 2017,
TB caused an estimated number of 1.3 million deaths among HIV-negative people.
In addition, there were an additional number of 300, 000 deaths from TB among
HIV-positive people. Moreover, there were an estimated number of 10.0 million
new TB cases equal to 133 cases per 100, 000 population, worldwide.5 The rapid
spread of infections and the alarming growth of drug resistants, especially the
emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-
resistant tuberculosis (XDR-TB) strains, have sounded the alarm to ﬁnd more
new potent drugs; therefore, ﬁnding an alternative approach to the controlling and
treatment of TB has become extremely vital.6 Phage therapy can be considered as a
signiﬁcant alternative to antibiotics for treating MDR and XDR pathogens.7 The
natural and useful capacity of bacteriophages to infect mycobacterial hosts, as well
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as their ability to kill Mycobacterium spp, has involved
numerous research studies for investigaing the phage ther-
apy as a novel therapeutic/diagnosis approach to myco-
bacterial infections.1,6 However, approapriately relevant
data about the efﬁciency of phage therapy in treating
various mycobacterial infections, especially TB, are lar-
gely scarce and limited. In this study, a comprehensive
review of the literature has been conducted to identify in
vitro and in vivo studies associated with the phage therapy
in the mycobacterial infection.
Phage therapy
The increasing emergence of infection, coinfection, and drug-
resistant pathogens has become a severe challenge for scien-
tists and public health.8,9 In recent years, several novel alter-
native strategies including therapeutic enzymes, pigments,
phytochemicals, antimicrobial polymers, antimicrobial pep-
tides, and silver nanoparticles have led researchers to consider
the treatment of infections in the presence of MDR and XDR
pathogens.1,10,11 However, since drug-resistant bacteria have
become increasingly problematic and challenging, phage ther-
apy is considered to be an important candidate for alternative
therapy.12 Bacteriophages are viruses that are isolated from
several ecological specimens including sewage, soil, and
water.13–15 The isolation of bacteriophage from an environ-
mental sample revealed that bacteriophages did not exert
adverse effects on individuals.15–17 It is estimated that there
are more than 4200 bacteriophages that exactly infect
Mycobacterium spp; it is expected that 1025 phage launches
a new infection cycle in every second of the day.18 The
application of bacteriophage as a candidate for alternative
therapy in non-mycobacterial infection was discovered in the
early 20th century, showing that bacteriophage has a high
capacity to efﬁciently eradicate pathogenic bacteria.12,19,20
However, information about the use of phages in the
treatment of bacterial infection in humans is little. Phages
are considered to be a good candidate in treating and
controlling mycobacterial infections; however, these
agents have several advantages and limitations for use in
humans.21–23 The main advantages and characteristics of
bacteriophages are as follows: I) phages cannot infect
human cells and replicate only in the target bacterium;
II) the selected phage perfectly lyses the pathogen at the
site of infection; III) the administration of phages is easier
and, after the initial administration, the concentration of
phages increases at the site of infection; therefore, very
few doses are required;24–26 III) similar to phages TM4
and D29, the selected phage should be highly virulent
against Mtb; IV) a non-pathogenic phage should be used
in phage therapy; and V) the selected phage should not
trigger an immune response and their effects are limited to
the site of infection.13,20,27 On the other hand, the use of
bacteriophages in humans is subject to several limitations
as follows: I) identifying a phage with therapeutic char-
acteristics and demonstrating that a phage is speciﬁc to a
given bacterial strain is very difﬁcult;21,28 II) the appear-
ance and development of bacterial resistance against
phages is theoretically possible, and the production of
phage genome without antibiotic-resistant gene, genes
encoded bacterial virulence factors, and integrase genes
(or without genes for phage-encoded toxins) is
complicated;21,29 III) the formulation and stabilization of
pharmaceutical preparations of phages is difﬁcult and has
several problems;30 IV) it is possible that lysogenic phages
integrate their DNA into the bacterial genome and hori-
zontally transfer resistant genes to the bacteria; therefore,
new resistant bacteria can develop.31,32 It can be con-
cluded that phages can perhaps set the ground for the
emergence and development of antibiotic resistance; and
V) it is possible for the immune system to lead to the
reduced activity of phages under the in vivo condition.33,34
Results of the previously published studies revealed that
phage therapy could be very effective against different
pathogenic bacteria such as Pseudomonas aeruginosa,
Acinetobacter baumannii, Staphylococcus aureus, and
Escherichia coli.35–38 However, there are limited studies
and data about the role of phage therapy in the treatment
of mycobacterial infections.
Is mycobacterium smegmatis the
ideal delivery system in phage
therapy?
Mycobacterium smegmatis (M. smegmatis) is a nonvirulent
fast-growing mycobacterium that does not infect people with
disease, even immunosuppressed peoples.39 Since bacterio-
phages do not have the ability to spread throughout the
membrane, several strategies are required to deliver the bac-
teriophage to the intracellular pathogenic bacteria.20,40 The
use of nonvirulent mycobacterium, especiﬁcallyM. smegma-
tis as a delivery system, is one of the main strategies used for
the treatment of mycobacterial infection (Figure 1).41 In the
phage therapy process, M. smegmatis plays several roles: I)
M. smegmatis acts as a carrier to deliver phage to the intra-
cellular pathogen; II)M. smegmatis can act as a host and lead
to the high proliferation of bacteriophage; III) this organism
Azimi et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Infection and Drug Resistance 2019:122944
increases bacteriophage infection rates; and IV)M. smegma-
tis is an appropriate environment for bacteriophage activity
within mononuclear cells such as macrophages and
monocytes.13,42 Based on the above, it can be concluded
that, in phage therapy, the use of nonvirulent M. smegmatis
in intracellular infection treatment is a better choice, and this
result can be seen as “proof of concept” that opens up new
opportunities for further research.
Phage therapy in tuberculosis
The emergence of MDR and XDR M. tuberculosis and the
limitation of ﬁnding more potent drugs and alternate thera-
peutics for the treatment of TB have attracted different
research groups to investigate the bacteriophage roles as a
suitable alternative to antibiotics in the treatment of TB.6,43
According to the natural capability to infect and kill myco-
bacteria, bacteriophages can be considered as an appropriate
alternative to antibiotics.42 Different bacteriophages were
investigated against TB as therapeutic options as follows:
1) Phage DS-6A; 2) Phage TM4; 3) Phage D29; 4) Phage T7;
5) Phage P4; 6) Phage PDRPv; 7) Phage BTCU-1; 8) Phage
Bo4; 9) Phage SWU1; 10) Phage GR-21/T; 11) Phage My-
327; 12) Phage Ms6; and 13) Phage Bxz2. In this review
article, the role of important mycobacteriophages in the
treatment of mycobacterial infection, especiﬁcally tubercu-
losis disease, is explained (Table 1).
Phage DS-6A
Mycobacteriophage DS6A has a high speciﬁcity to mem-
bers of the Mycobacterium tuberculosis complex (MTBC),
and this unique feature makes this bacteriophage an impor-
tant and interesting candidate for anti-TB therapy.44 This
mycobacteriophage can form plaque only on mycobacteria
belonging to the MTBC.45 The results of the previously
published studies have shown that the treatment of Mtb
infection with mycobacteriophage DS6A has led to a
reduction in infection in liver, spleen, and lung lesions; it
has shown a high ability to competently eliminate Mtb
from infectious sites.44,46 In this scenario, it is presumed
that phage-infected Mtb cells may brieﬂy transport myco-
bacteriophage DS6A to Mtb bacilli within macrophages
(Figure 1).13,46 However, more in-vitro and in-vivo studies
are required to shed light on the mechanisms that phage
uses for Mtb eradication.
Phage TM4
The length of the mycobacteriophage TM4 genome is
nearly 52,797 bp, which encodes several proteins with
different functions.42 The proteins encoded by TM4 are
similar to transcriptional regulators or bear a high similarity
to haloperoxidases and glutaredoxins.47 TM4 is a lytic
bacteriophage with double-stranded DNA and an extensive
host range that could infect both slow-growing and fast-
Figure 1 Steps involved in phage mediated Mycobacterium tuberculosis lysis using Mycobacterium smegmatis.
Dovepress Azimi et al
Infection and Drug Resistance 2019:12 submit your manuscript | www.dovepress.com
DovePress
2945
T
ab
le
1
T
he
lis
t
of
m
yc
ob
ac
te
ri
op
ha
ge
s
us
ed
ag
ai
ns
t
M
yc
ob
ac
te
ri
a
in
fe
ct
io
ns
:t
ar
ge
ts
,m
ec
ha
ni
sm
s,
an
d
re
su
lts
of
ph
ag
e
th
er
ap
y
P
h
ag
es
T
ar
ge
ts
M
ec
h
an
is
m
s
R
es
u
lt
s
o
f
p
h
ag
es
th
er
ap
y
D
S-
6A
M
yc
ob
ac
te
riu
m
tu
be
rc
ul
os
is,
M
yc
ob
ac
te
riu
m
ul
ce
ra
ns
●
Pl
aq
ue
fo
rm
at
io
n
on
m
yc
ob
ac
te
ri
a
be
lo
ng
in
g
to
th
e
M
T
BC
●
R
ed
uc
tio
n
of
in
fe
ct
io
n
in
liv
er
,s
pl
ee
n
an
d
lu
ng
le
si
on
s.
●
C
om
pl
et
e
El
im
in
at
io
n
of
M
tb
fr
om
in
fe
ct
io
ns
si
te
s.
●
Im
pr
ov
em
en
t
of
le
si
on
s
(in
fe
ct
io
n
re
du
ct
io
n)
in
lu
ng
s,
sp
le
en
an
d
liv
er
s
in
BU
.
T
M
4
M
yc
ob
ac
te
riu
m
tu
be
rc
ul
os
is,
M
yc
ob
ac
te
riu
m
av
iu
m
●
U
nk
no
w
n
●
Ly
si
ng
an
d
ki
lli
ng
M
.a
viu
m
in
si
de
m
on
on
uc
le
ar
ce
lls
su
ch
as
m
ac
ro
-
ph
ag
es
an
d
m
on
oc
yt
es
.
●
Li
po
so
m
al
-d
el
iv
er
ed
m
yc
ob
ac
te
ri
op
ha
ge
T
M
4
co
ul
d
ha
ve
di
re
ct
ac
ce
ss
to
in
tr
ac
el
lu
la
r
M
tb
,ﬁ
na
lly
de
st
ro
yi
ng
th
e
in
tr
ac
el
lu
la
r
pa
th
og
en
.
●
Tr
ea
tm
en
t
of
M
.a
viu
m
in
fe
ct
ed
m
ac
ro
ph
ag
es
w
ith
T
M
4
co
nt
ri
bu
te
d
to
a
co
ns
id
er
ab
le
de
cr
ea
se
in
th
e
nu
m
be
r
of
M
.a
viu
m
ba
ci
lli
.
D
29
M
yc
ob
ac
te
riu
m
tu
be
rc
ul
os
is,
M
yc
ob
ac
te
riu
m
ul
ce
ra
ns
●
Ly
si
n
A
hy
dr
ol
yz
in
g
pe
pt
id
og
ly
ca
n
of
M
tb
.
●
Ly
si
n
B
di
ss
em
in
at
in
g
m
yc
ol
ic
ac
id
fr
om
th
e
pe
pt
id
og
ly
ca
ns
in
M
tb
ce
ll
w
al
l.
●
In
du
ci
ng
a
ce
llu
la
r
in
ﬁ
ltr
at
e
of
a
m
ac
ro
ph
ag
ic
/ly
m
ph
oc
yt
ic
pr
oﬁ
le
in
BU
.
●
D
29
ha
vi
ng
an
ex
te
ns
iv
e
ly
tic
ac
tiv
ity
ag
ai
ns
t
m
yc
ol
ac
to
ne
-p
ro
du
ci
ng
M
.u
lc
er
an
s.
●
D
29
in
cr
ea
si
ng
th
e
le
ve
ls
of
T
N
F,
IF
N
-γ
,a
nd
IL
-1
0.
●
D
29
re
su
lti
ng
in
th
e
in
cr
ea
se
an
d
m
ai
nt
en
an
ce
of
a
lo
ca
l
m
on
o-
nu
cl
ea
r
in
ﬂ
am
m
at
or
y
re
sp
on
se
to
M
.u
lc
er
an
s.
●
C
om
pl
et
e
El
im
in
at
io
n
of
M
tb
fr
om
in
fe
ct
io
ns
si
te
s.
●
M
yc
ob
ac
te
riu
m
ul
ce
ra
ns
ly
se
d
an
d
er
ad
ic
at
ed
du
e
to
th
e
ly
tic
ac
tiv
ity
of
ph
ag
e.
●
R
ed
uc
tio
n
of
th
e
pr
ol
ife
ra
tio
n
of
th
e
m
yc
ol
ac
to
ne
-p
ro
du
ci
ng
M
.
ul
ce
ra
ns
.
T
7
M
yc
ob
ac
te
riu
m
tu
be
rc
ul
os
is
●
G
p2
bi
nd
in
g
to
th
e
β
su
bu
ni
t
of
R
N
A
po
ly
m
er
as
e
an
d
pr
ev
en
tin
g
tr
an
sc
ri
pt
io
n
by
in
hi
bi
tio
n
in
iti
al
iz
at
io
n
of
th
e
na
sc
en
t
R
N
A
tr
an
sc
ri
pt
.
●
G
p2
pr
ev
en
ts
th
e
en
zy
m
at
ic
ac
tiv
ity
of
M
tb
R
N
A
po
ly
m
er
as
e.
●
T
7
ef
fe
ct
iv
el
y
ki
lls
th
e
M
tb
.
P4
M
yc
ob
ac
te
riu
m
tu
be
rc
ul
os
is
●
Ba
ct
er
io
ph
ag
e
P4
ca
ps
id
pr
ot
ei
n
Ps
u
in
hi
bi
tin
g
A
T
Pa
se
an
d
tr
an
sl
o-
ca
se
ac
tiv
iti
es
of
th
e
R
ho
pr
ot
ei
ns
in
tw
o
w
ay
s:
●
I)
T
he
bi
nd
in
g
of
Ps
u
to
R
ho
pr
ot
ei
ns
ca
us
in
g
R
ho
pr
ot
ei
ns
to
be
un
ab
le
to
te
rm
in
at
e
w
ith
a
R
ho
-d
ep
en
de
nt
te
rm
in
at
or
.
●
II)
Ps
u
vi
a
di
re
ct
in
te
ra
ct
io
n
w
ith
R
ho
pr
et
ee
ns
pr
ev
en
tin
g
th
e
re
le
as
e
of
R
N
A
fr
om
a
st
al
le
d
el
on
ga
tio
n
co
m
pl
ex
.
●
P4
ca
n
ef
fe
ct
iv
el
y
ki
ll
th
e
M
tb
.
PD
R
Pv
M
yc
ob
ac
te
riu
m
tu
be
rc
ul
os
is
●
U
nk
no
w
n
●
Ph
ag
e
PD
R
Pv
sh
ow
ed
a
ly
tic
ac
tiv
ity
ag
ai
ns
t
M
tb
.
(C
on
tin
ue
d)
Azimi et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Infection and Drug Resistance 2019:122946
T
ab
le
1
(C
on
tin
ue
d)
.
P
h
ag
es
T
ar
ge
ts
M
ec
h
an
is
m
s
R
es
u
lt
s
o
f
p
h
ag
es
th
er
ap
y
BT
C
U
-1
M
yc
ob
ac
te
riu
m
tu
be
rc
ul
os
is
●
BT
C
U
-1
en
co
di
ng
tw
o
en
do
ly
si
ns
as
fo
llo
w
s:
●
I)
T
he
cl
ea
va
ge
of
th
e
pe
pt
id
og
ly
ca
n
in
th
e
ce
ll
w
al
lo
f
m
yc
ob
ac
te
ri
a
is
do
ne
by
lys
A.
●
II)
T
he
re
le
as
e
of
fr
ee
m
yc
ol
ic
ac
id
fr
om
th
e
m
yc
ol
yl
ar
ab
in
og
al
ac
ta
n
bo
nd
is
ca
rr
ie
d
ou
t
by
lys
B.
●
Ly
sA
an
d
lys
B
ha
ve
an
tim
ic
ro
bi
al
ac
tiv
ity
an
d
m
ak
e
si
gn
iﬁ
ca
nt
ch
an
ge
s
in
th
e
ce
ll
sh
ap
e
of
M
tb
.
●
T
he
se
en
do
ly
si
ns
er
ad
ic
at
e
m
os
t
of
M
tb
du
ri
ng
th
e
co
ur
se
of
th
ei
r
lif
e
cy
cl
e.
Bo
4
M
yc
ob
ac
te
riu
m
tu
be
rc
ul
os
is,
N
T
M
,
M
yc
ob
ac
te
riu
m
bo
vis
●
Bo
4
ha
s
an
tim
ic
ro
bi
al
ac
tiv
ity
an
d
co
ul
d
ly
se
an
d
ef
fe
ct
iv
el
y
ha
lts
th
e
gr
ow
th
of
M
tb
●
A
ly
tic
ph
ag
e
po
ss
ib
ly
er
ad
ic
at
es
M
tb
in
in
fe
ct
io
us
si
te
s.
SW
U
1
M
yc
ob
ac
te
riu
m
tu
be
rc
ul
os
is
●
In
hi
bi
tin
g
th
e
lip
id
m
et
ab
ol
is
m
an
d
pr
ev
en
tin
g
th
e
us
ua
lp
ro
du
ct
io
n
of
lo
ng
-c
ha
in
fa
tt
y
ac
id
s.
●
In
cr
ea
si
ng
th
e
ce
ll
w
al
lp
er
m
ea
bi
lit
y
an
d
po
te
nt
ia
tin
g
th
e
ef
ﬁ
ci
en
cy
of
m
ul
tip
le
an
tib
io
tic
s.
●
In
cr
ea
si
ng
th
e
su
sc
ep
tib
ili
ty
of
M
tb
ag
ai
ns
t
he
at
sh
oc
k,
H
2O
2,
SD
S,
an
d
lo
w
PH
.
●
C
ha
ng
in
g
co
lo
ny
fo
rm
at
io
n
an
d
bi
oﬁ
lm
m
or
ph
ol
og
y.
●
SW
U
1g
p3
9
an
d
gp
67
m
ig
ht
be
in
cl
ud
ed
as
a
br
oa
d-
sp
ec
tr
um
an
ti-
bi
ot
ic
ad
ju
va
nt
or
po
te
nt
ia
to
r.
G
R
-2
1/
T
M
yc
ob
ac
te
riu
m
tu
be
rc
ul
os
is
●
U
nk
no
w
n
●
R
ed
uc
tio
n
of
in
fe
ct
io
n
in
liv
er
,s
pl
ee
n
an
d
lu
ng
le
si
on
s.
M
y-
32
7
M
yc
ob
ac
te
riu
m
tu
be
rc
ul
os
is
●
U
nk
no
w
n
●
R
ed
uc
tio
n
of
in
fe
ct
io
n
in
liv
er
,s
pl
ee
n
an
d
lu
ng
le
si
on
s.
M
s6
M
yc
ob
ac
te
riu
m
sm
eg
m
at
is,
M
yc
ob
ac
te
riu
m
tu
be
rc
ul
os
is
M
yc
ob
ac
te
riu
m
bo
vis
,B
C
G
●
Si
m
ila
r
to
th
e
ph
ag
e
D
29
,L
ys
in
A
hy
dr
ol
yz
in
g
pe
pt
id
og
ly
ca
n
of
M
tb
ce
ll
w
al
l.
●
Ly
sB
en
co
di
ng
a
pr
ot
ei
n
w
ith
lip
ol
yt
ic
ac
tiv
ity
th
at
hy
dr
ol
yz
es
a
w
id
e
sp
ec
tr
um
of
fa
tt
y
ac
id
es
te
rs
in
M
tb
.
●
C
le
av
ag
e
of
es
te
r
bo
nd
am
on
g
ar
ab
in
og
al
ac
ta
n
an
d
m
AG
P.
●
C
le
av
ag
e
of
th
e
es
te
r
bo
nd
be
tw
ee
n
tr
eh
al
os
e
an
d
m
yc
ol
ic
ac
id
s
in
T
D
M
.
●
Ly
sA
an
d
lys
B
ha
ve
an
tim
ic
ro
bi
al
ac
tiv
ity
,a
nd
th
es
e
en
do
ly
si
ns
er
ad
i-
ca
te
m
os
t
of
M
tb
du
ri
ng
th
e
co
ur
se
of
th
ei
r
lif
e
cy
cl
e.
Bx
z2
M
yc
ob
ac
te
riu
m
ul
ce
ra
ns
●
U
nk
no
w
n
●
Bx
z2
ha
s
th
e
hi
gh
es
t
ly
tic
ac
tiv
ity
ag
ai
ns
t
M
yc
ob
ac
te
riu
m
ul
ce
ra
ns
.
A
b
b
re
vi
at
io
n
s:
BC
G
,
Ba
ci
lle
C
al
m
et
te
G
ué
ri
n;
M
T
BC
,
M
yc
ob
ac
te
riu
m
tu
be
rc
ul
os
is
co
m
pl
ex
;
M
tb
,M
yc
ob
ac
te
riu
m
tu
be
rc
ul
os
is;
BU
,
Bu
ru
li
U
lc
er
;
T
N
F-
α,
Tu
m
or
ne
cr
os
is
fa
ct
or
al
ph
a;
IF
N
-γ
,
In
te
rf
er
on
ga
m
m
a;
N
T
M
,
N
on
-t
ub
er
cu
lo
si
s
m
yc
ob
ac
te
ri
um
;m
AG
P,
M
yc
ol
yl
-a
ra
bi
no
ga
la
ct
an
-p
ep
tid
og
ly
ca
n;
T
D
M
,T
re
ha
lo
se
6,
6′
-d
im
yc
ol
at
e.
Dovepress Azimi et al
Infection and Drug Resistance 2019:12 submit your manuscript | www.dovepress.com
DovePress
2947
growing strains of mycobacteria.48 Based on the results of
studies that evaluated the gene expression and codon usage
in different mycobacteriophages, it is revealed that myco-
bacteriophage TM4 extremely expresses genomes and has
probably the strongest capability to eradicate mycobacteria
strains in infectious sites.49 In addition to the problem of
MDR and XDR Mtb strains, these bacteria infect macro-
phages and monocytes and grow within them. Finally, in
macrophages and monocytes, Mtb begins a dormant or
latent phase of infection and produces the restriction effects
of used antibiotics against Mtb infections.48 Overall, all
mycobacteriophages are not able to penetrate eukaryotic
cells, and this limitation against intracellular bacterial infec-
tion, such as TB, leads to the introduction and development
of a novel vector for phage delivery into intracellular
infections.42 Recently, researchers have used the liposomes
as a delivery system to transport bacteriophage into patho-
gen-infected cells.50 Liposomes have signiﬁcant cell
penetration features and, therefore, are quite possible to be
an appropriate envelope for phages used against intracellu-
lar bacteria, especially Mtb.42,50 Results of a previously
published study revealed that liposomes penetrated into
infected cells by endocytosis and were found within early
endosomes after penetration.51 Mycobacteriophage TM4
has the ability to destroy the intracellular pathogen.52
Since liposomal-delivered mycobacteriophage TM4 could
have direct access to intracellular Mtb,42 it is concluded that
liposome is a proper vector for mycobacteriophage TM4
therapy of intracellular Mtb infection (Figure 2).
Phage D29
The ability of mycobacteriophage D29 to quickly penetrate
and eradicate pathogens is the reason why researchers have
considered it as a new therapeutic option against MDR and
XDR bacteria, especially Mtb.53 This mycobacteriophage is
used for several targets, particularly in TB diagnosis and
Figure 2 Steps involved in phage TM4 mediated Mycobacterium tuberculosis lysis using liposome.
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probably in TB treatment.54 In the mycobacteriophage D29
genome, there are three genes that make the lytic cassette.
These three genes encode Lysin A, Lysin B, and holin
protein.55,56 Lysin A coded by gp10 hydrolyzes peptidogly-
can of bacterial cell walls.57 Gp12 encodes Lysin B that
leads to the dissemination of mycolic acid from the pepti-
doglycans in mycobacterial cell wall.53,58 Holin as a mem-
brane pore-forming protein participates in the transfer of
lysins from the cytosol to the periplasm.59 Lysin A of
mycobacteriophage D29 has three main domains including
NTD (lethal to M. smegmatis), LD with catalytic activity in
N terminus, and one domain present at the C terminus.
Speciﬁcally, the C-terminal domain of Lysin A binds to
Mtb peptidoglycan and hydrolyzes it.55,57 Therefore, these
molecules (LysinA, LysinB, and holin) are potential candi-
dates that develop phage-based therapeutics against Mtb
infections (Figure 3).
Phage T7
Bacteriophage T7, an obligate lytic phage, was deﬁned in
1945 as one of the several different bacteriophages that
infects and replicates in Escherichia coli.60 Bacteriophage
T7 enjoys several advantages that make it a suitable model
system for genome strategy and engineering. These advan-
tages are as follows: 1) T7 is relatively independent of
complex host physiology, and 2) most of the T7 genomes
are transported into a newly infected cell through RNA
polymerase.61,62 Six important proteins formed the main
T7 phage particle including I) gp10A as a primary capsid
protein; II) gp10B as a secondary capsid protein; III) gp8
as a connector; IV) gp17 as a tail ﬁber; and V) gp11 and
gp12 as tail proteins.60,63 A new method for treating
infectious diseases, such as TB, is used to deﬁne how
bacteriophages can be effective in killing bacterial cells.
Bacteriophages could produce small encoded proteins that
bind to RNA polymerase.64 RNA polymerase is responsi-
ble for transcription in microorganism, and the binding of
the small phage-encoded proteins to RNA polymerase
leads to the suppression of bacterial gene transcription.
T7 phage protein, Gp2, encoded by the rpoC gene, in
Escherichia coli, binds to the section including amino
acids 1145–1198 in the beta-prime subunit of RNAP,
thus inhibiting the productive engagement of RNA poly-
merase with the promoter.65–68 Gp2 prevents the enzy-
matic activity of bacterial RNA polymerase by several
mechanisms in the following fashion: I) Gp2 inhibits
functionally necessary alterations in RNA polymerase; II)
Gp2 inhibits the interaction between catalytic site of RNA
polymerase and DNA; III) in the DNA binding channel,
Gp2 inhibits the binding of DNA.64 One of the main
antibiotics used in TB treatment is rifampicin. Results of
an in silico study revealed that, in the case of Mtb infec-
tion, Gp2, similar to rifampicin, binds to the β subunit of
RNA polymerase, encoded by the rpoB gene; in addition,
Figure 3 Overview of phage D29 mediated Mycobacterium tuberculosis lysis.
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it prevents transcription by inhibiting the nascent RNA
transcript, yet to a lesser degree than that in Escherichia
coli (Figure 4).64,69
Phage P4
Rho is a homohexameric transcription terminator in various
pathogens including Gram-negative and Gram-positive bac-
teria that regulates gene expression and many physiological
processes and is a potential antibiotic target.70–74
Accordingly, Rho is involved in many physiological pro-
cesses; therefore, the inhibition of this transcription termina-
tor could be beneﬁcial as a synergistic antimicrobial
treatment strategy.75 In different bacteria such as
Escherichia coli, Psu is a bacteriophage P4 capsid protein
that acts as an unconventional capsid organizing protein and
inhibits ATPase and translocases activities of these Rho
proteins.76 In recent years, the results of a study revealed
that the Rho-dependent termination had the main role in the
pathogenicity of Mtb.77 Similar to the same bacteria, in Mtb,
Psu binds to Rho protein and antagonizes Rho in trans by
forming a mechanical interference to Rho translocation
(Figure 5).78 In total, the expression of Psu can kill various
bacteria such as Mtb in two ways: I) the binding of Psu to
Rho proteins makes Rho proteins unable to terminate with a
Rho-dependent terminator; II) Psu through direct interaction
with Rho proteins prevents the release of RNA from a stalled
elongation complex.76 Hence, Psu could be useful as a
synergistic antibiotic treatment against Mycobacterium.
Phage PDRPv
So far, twenty-seven clusters of mycobacteriophages have
been identiﬁed in the Actinobacteriophage database
(Phagesdb.org). Mycobacteriophages (PDRPv) belong to
Siphoviridae family and B1 sub-cluster. The length of the
mycobacteriophage PDRPv genome is approximately
69,110 bp with a G+C content of ~66%, containing 106
open reading frames (ORFs).12,79 The results of another
study revealed that phage PDRPv had a lytic activity
against Mtb. However, the exact anti-tuberculosis mechan-
ism of this phage was not determined.12
Phage BTCU-1
Mycobacteriophage BTCU-1 belongs to Siphoviridae
family and has been isolated from soil specimen, obtained
from eastern Taiwan.80 The length of the mycobacterioph-
age BTCU-1 genome is approximately 46 kb, and this
bacteriophage has a linear double-stranded DNA with an
icosahedral head and a very long tail.81 The genome of
BTCU-1 encodes several proteins with predeﬁned func-
tions. One of these proteins is identiﬁed as a putative phos-
phoribosyl transferase (PRT) and is particularly found in
mycobacteriophages that infect Mycobacterium.80,82 These
Figure 4 Steps involved in phage T7 mediated Mycobacterium tuberculosis lysis.
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proteins eradicate most bacteria during the course of their
life cycle.80 Moreover, different mycobacteriophages encode
lytic endolysins that have antimicrobial activity and can be
effective against MDR and XDR MTB strains.83–85 BTCU-
1_ORF7 (lysA) and BTCU-1_ORF8 (lysB) are two presumed
lytic genes in the genome of mycobacteriophage BTCU-1
that encode two endolysins with antimycobacterial
activities.81 These endolysins possess two separate basic
functions. The cleavage of the peptidoglycan in the cell
wall of mycobacteria is done by lysA. On the other hand, it
is presumed that the release of free mycolic acid from the
mycolylarabinogalactan bond is carried out by lysB.81,86
Finally, it can be concluded that lysA and lysB can make
signiﬁcant changes in the cell shape of mycobacterium, and
these ﬁndings recommend that these endolysins are good
candidates for treating and controlling mycobacterial infec-
tions (Figure 6).
Phage Bo4
The length of the mycobacteriophage Bo4 genome is
approximately 39,318 bp, and this bacteriophage has a
dsDNA genome with a G+C content of 66.76%. It is
identiﬁed that genome of mycobacteriophage Bo4 contains
58 ORFs.87 This mycobacteriophage has a long noncon-
tractile tail with isometric and icosahedral heads.87,88
These features revealed that mycobacteriophage Bo4
could be considered as a lytic phage that infected and
possibly eradicated pathogenic mycobacteria in the
infected sites. Moreover, this phage can be a valuable
tool for phage typing of Mtb.89 Different mycobacterial
species including non-tuberculosis mycobacterium
(NTM), mycobacterium bovis, and Mtb can be infected
by this mycobacteriophages.87 However, mycobacterioph-
age Bo4 has the capability to infect MDR and XDR Mtb.
In vivo conditions, in blood, and in lysosomal macro-
phages, Bo4 could lyse and effectively halt the growth of
Mtb, showing that mycobacteriophage Bo4 has antimicro-
bial activity.87 Finally, these features make it an ideal
candidate and a potentially useful tool for diagnosing and
developing phage-based anti-TB therapies (Figure 1).
Phage SWU1
In recent years, a novel mycobacteriophage SWU1 has been
isolated from environmental samples, especially from a soil
sample in China using M. smegmatis mc2155 as the host
microorganism.90 The length of the mycobacteriophage
SWU1 genome is approximately 52,474 bp with a G+C
content of 62.4%, containing 94 and 3 candidate protein-
coding and tRNA genes, respectively.91 SWU1gp39 is a
new gene from mycobacteriophage SWU1, which is absent
in other mycobacteriophages and the exact function of this
gene has not yet been determined.41 Overall, the degree of
antibiotic resistance in Mtb is closely related to cell wall
permeability. SWU1gp39 can inhibit the lipid metabolism
of Mycobacterium and prevent the usual production of
long-chain fatty acids.41,92 Therefore, SWU1gp39 could
increase the cell wall permeability in Mtb and potentiate
the efﬁciency of multiple antibiotics such as rifampicin,
Figure 5 Overview of phage P4 mediated Mycobacterium tuberculosis lysis.
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isoniazid, vancomycin, oﬂoxacin, ciproﬂoxacin, norﬂoxa-
cin, ampicillin, and erythromycin.41 Moreover, SWU1gp39
increases the susceptibility of Mtb to various stresses
including heat shock, H2O2, SDS, and low PH.41,93 On
the other hand, a putative GTPase-activating protein
(GAP) is encoded with mycobacteriophage SWU1
A321_gp67.94 The GAP superfamily comprises 6 subfami-
lies including Ras, Rho, Ran, Rab, Rheb, and ARF.95 These
proteins can be involved in several processes including
signal transduction, cell differentiation, cell cycle, and pro-
tein synthesis through regulating the activity of GTPase.96
Gp67 is a mycobacteriophage SWU1 late-stage gene that
could change colony formation and bioﬁlm morphology and
may play a role in the reproduction and release of the phage
progeny.97 Gp67 can downregulate the transcription of var-
ious genes such as MSMEG_0235, MSMEG_6092,
MSMEG_1876, and mmpL4b.94 These genes have multiple
roles in bioﬁlm formation, cell wall integrity, and develop-
ment of colony morphology.98 Moreover, gp67 can increase
the susceptibility of Mtb against different antibiotics such as
streptomycin and capreomycin via several procedures
including (a) making changes in cell wall integrity and
cell wall structure and (b) preventing and disrupting bioﬁlm
formation.94 In total, it can be concluded that SWU1gp39
and gp67 might be utilized as a broad-spectrum antibiotic
adjuvant or potentiator and be included into the existing
antibiotic regimen for better control and greater efﬁciency
of anti-tuberculosis drugs (including isoniazid and rifampi-
cin) in bacterial killing (Figure 7).
Phage Ms6
Mycobacteriophage Ms6 is a temperate phage with a
linear double-stranded DNA that has a lytic cassette
composed of ﬁve genes.99,100 Similar to the phage D29,
in Ms6, Lysin A (a 384 amino acid polypeptide) has a
central peptidoglycan recognition protein (PGRP) in a
super-family conserved domain and hydrolyzes peptido-
glycan of bacterial cell walls.101 Ms6 Gp1 is highly
similar to a chaperone-like protein and participates in
the transport of LysA to the extracytoplasmic setting.43
In the lysis cassette, Ms6 LysB is localized between lysA
and hol genes. The length of Ms6 LysB is 996 bp that
encodes a protein with lipolytic activity and possesses a
capability to hydrolyze a wide spectrum of fatty acid
esters.99–102 Results of several studies revealed that, in
M. smegmatis, Ms6 LysB targets the outer membrane,
leading to the cleavage of ester bond among arabinoga-
lactan and mycolic acids in the mycolyl-arabinogalactan-
Figure 6 Overview of phage BTCU-1 mediated Mycobacterium tuberculosis lysis.
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peptidoglycan (mAGP) complex.58,101,102 Moreover, in
Mycobacterium tuberculosis H37Ra and Mycobacterium
bovis BCG, Ms6 LysB leads to the cleavage of the ester
bond between trehalose and mycolic acids in trehalose
6,6′-dimycolate (TDM).101 In addition to LysA (gp2) and
LysB (gp1 and gp3), in Ms6 lytic cassette, holin is
encoded by gp4 (hol).99 In Ms6, holin protein has several
roles including controlling the activation of the endolysin
and controlling the access of endolysin to murein.43,103
Finally, according to the above-mentioned statements, it
can be concluded that mycobacteriophage Ms6 with dif-
ferent endolysins is a worthy candidate in Mtb infection
therapy (Figure 8).
Phage therapy in mycobacterium
avium infections
Mycobacterium avium (M. avium) is the slowest growing
intracellular pathogen that replicates and persists within the
mononuclear phagocytes.104,105 This pathogen causes the
dissemination of infection in immunocompromised patients.
The patients with acquired immune deﬁciency syndrome
(AIDS), especially patients with <50 CD4+ T cells/mm3,
are susceptible to disseminated infection caused by this
organism.106 However, disseminated infections caused by
M. avium have been reported to be highly frequency in
non-AIDS individuals.48 The application of protease inhibi-
tors in the treatment of human immunodeﬁciency virus (HIV-
1) infection has a substantial effect and contributes to a
signiﬁcant reduction in the occurrence of M. avium
bacteremia.107 Nevertheless, when the anti-HIV treatment
stops, the incidence of M. avium bacteremia increases.108
M. avium shows resistance to a wide range of antituberculo-
sis antibiotics, and merely a few antibiotics including clari-
thromycin, azithromycin, and roxithromycin (Macrolides)
have shown activities againstM. avium in vitro and in vivo.48
On the other hand, the other problem is thatM. avium is able
to infect and replicate within mononuclear cells including
macrophages and monocytes.109 The intracellular growth of
organism within macrophages and monocytes justiﬁes the
latent phase of infection in the host.48 Therefore, the anti-
microbial agents that require a microbial target in active
replication are not able to eradicate these infections. Of
note, it is important for the new alternative therapies to be
evaluated from the viewpoint of the following two facts: 1)
clarithromycin, azithromycin, and roxithromycin are used in
the prophylactic form for the M. avium infection, and the
emergence of resistance in one antibiotic will be equal to
resistance to all macrolides and 2) intracellular growth of
organism.110 The use of bacteriophage against M. avium
infection is a signiﬁcant alternative and is useful as an anti-
mycobacterial regimen for treating drug-resistant bacteria.109
TM4 is a lytic mycobacteriophage that infectsM. avium and
does not form persistent lysogens.42,111 TM4 can be deliv-
ered by a nontuberculous mycobacterium (Mycobacterium
Figure 7 Overview of phage SWU1 mediated Mycobacterium tuberculosis lysis.
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smegmatis) and has the ability to lyse and kill M. avium
inside mononuclear cells such as macrophages and
monocytes.48 It has been described previously that the treat-
ment of M. avium infected macrophages with TM4 infected
M. smegmatis and contributed to a considerable decrease in
the number of M. avium bacilli.109 Moreover, the treatment
of M. avium infected macrophages with TM4 infected M.
smegmatis led to the fusion of vacuole concealing M. smeg-
matis infected by TM4 with the M. avium vacuole in
macrophages.48 However, accordingly, M. avium naturally
inhibits phagosome-lysosome fusion in macrophages, and it
is predictable that the mycobacterial vacuole still has the
capacity to be fused with endosomal.112 Results of another
study revealed that the coinfection of macrophage with M.
avium and Coxiella burnetti led to the fusion of the two
vacuoles and, ﬁnally, created new vacuoles that are acidic
and contain Coxiella andM. avium.113 Moreover, it is possi-
ble for TM4 to reach theM. avium vacuole in different ways,
and that when vacuoles are lysed, the bacteria-containing
vacuole becomes acidic.48,109 It can be concluded that these
ﬁndings proposed a new concept to kill intracellular myco-
bacteria and warrant the upcoming progression. However, it
appears that in order to understand the exact role of myco-
bacteriophage in M. avium infection treatment, further stu-
dies are required.
Phage therapy in mycobacterium
ulcerans infection
Buruli Ulcer (BU) is the third most common mycobacter-
ial infection in immunocompromised individuals, espe-
cially in HIV positive patients.52 This infectious disease
is caused by Mycobacterium ulcerans (M. ulcerans) and is
a serious and chronic necrotizing skin-infection disease,
which is reported to be active in more than 30 countries
worldwide with high frequency in West Africa.114,115
Although M. ulcerans is proposed as an extracellular
pathogen, evidence shows that this microorganism can be
found in macrophages throughout the initial phase of
infection.116 M. ulcerans secretes a lipidic exotoxin diag-
nosed as mycolactone. This lipid toxin was shown to be
cytopathic to cultured L929 murine ﬁbroblasts and
induced apoptosis in mammalian cells.117,118 Moreover,
this exotoxin was characterized by immunosuppressive
properties and, ﬁnally, led to the typically clinical sign of
ulcerative BU skin lesions.115,119 The clinical manifesta-
tion of BU is characterized by various forms including
preulcerative nodule, papules, plaque, and oedematous
lesions; these lesions can tend towards characteristic
necrotic ulcerative forms with undermined edges.114,116
According to the data on BU disease, the design and
preparation of controlling programs for prevention
Figure 8 Overview of phage MS6 mediated Mycobacterium tuberculosis lysis.
Azimi et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Infection and Drug Resistance 2019:122954
purposes can be very difﬁcult. Moreover, no vaccine
against BU is available so far; however, evidence has
shown that vaccination with Bacille Calmette-Guérin
(BCG) could provide temporary protection against
BU.120 To date, BU is conventionally treated by surgical
resection of affected skin followed by grafting, if
required.121 However, as of 2004, the World Health
Organization (WHO) recommended the combination of
antituberculosis drugs rifampicin and streptomycin as stan-
dard therapy for the treatment of BU patients.122 Although
the application of antituberculotic drugs decreases the
relapse rates, this treatment is susceptible to numerous
drawbacks: 1) this treatment does not resolve widespread
lesions and patients are often left with scars and lifelong
disabilities;123 2) muscular injection of streptomycin for a
long time requires skilled personnel; 3) the mutations
related to rifampicin resistance have already identiﬁed an
in-vivo experimental condition after monotherapy; 4) the
application of these antituberculosis drugs is related to
several adverse side effects; 5) the consumption of these
drugs may contribute to the deterioriation of the lesion
with paradoxical reactions or the emergence of new
lesions.124–128 The use of bacteriophages as a diagnostic
and treatment method for BU provides several beneﬁts for
patients: 1) extracellular microorganisms that prevail in
progressive lesions are lysed and eradicated due to the
lytic activity of phages; 2) phages can be administered
topically in necrotic infection sites for the treatment of
ulcerative lesions; and 3) M. ulcerans is naturally found
as an extracellular pathogen and, ﬁnally, this pathogen
might be nearly available by lytic phages.114,129 Among
different bacteriophages used for the treatment of bacterial
infections, plaques of phage D29 are comparatively large
and adsorption of phage particles seems to be efﬁcient,
which might be the best choice for the treatment of BU.52
Moreover, the use of phage DS-6A in animal models with
disseminated tuberculosis leads to the reduction of lesions
in lungs, spleen, and livers.114 Mycobacteriophage D29 is
a lytic phage, and the results of experimentally infected
animal models demonstrated that a single subcutaneous
inoculation of this phage reduced the proliferation of the
mycolactone-producing M. ulcerans 1615.52,114 Notably, it
is revealed that lytic activity of mycobacteriophage D29
may not be restricted to M. ulcerans 1615, and this phage
also shows the lytic activity against numerous other M.
ulcerans isolates in vitro.130 One of the main characteris-
tics of mycobacteriophage D29 is that this phage can be
detected in several organs including blood and spleen (in
post-injection 2 h) after subcutaneous injection.114
Moreover, mycobacteriophage D29 could be found in the
draining lymph nodes for longer periods of time (at least
15 days).114,130 Results of a previously published study
revealed that the application of mycobacteriophage D29 to
the treatment of BU in vivo led to the pathologic reduction
and the prevention of ulceration.114 In total, it can be
concluded that mycobacteriophage D29 reduces the num-
ber of M. ulcerans through several mechanisms: 1) myco-
bacteriophage D29 induces a cellular inﬁltrate of a
macrophagic/lymphocytic proﬁle; 2) mycobacteriophage
D29 has an extensive lytic activity against mycolactone-
producing M. ulcerans isolates, especially M. ulcerans
1615; 3) mycobacteriophage D29 increases the levels of
TNF, IFN-γ, and IL-10 in vivo; and 4) treatment with
mycobacteriophage D29 leads to the increase and main-
tenance of a local mononuclear inﬂammatory response to
M. ulcerans.114–116,131
Discussion and conclusion
The rapid prevalence of mycobacterial infections and
drug-resistance bacteria, especially the emergence of mul-
tidrug-resistant tuberculosis (MDR-TB) and extensively
drug-resistant tuberculosis (XDR-TB), has prompted
researchers to ﬁnd a novel alternative approach to control-
ling and treating TB. Mycobacteriophages are considered
as natural antibacterial agents and are parasites on bac-
teria. Moreover, mycobacteriophages are extremely speci-
ﬁc to their host. Therefore, phage therapy can be
considered as a novel candidate for treating and control-
ling mycobacterial infections. Although phage therapy is a
novel therapeutic approach against bacterial infection,
especially MDR and XDR bacteria, the clinical use of
this approach is susceptible to several limitations as fol-
lows: I) the administration of a large dose of phages in
patients probably leads to the onset of the immunological
response; therefore, this limitation restricts the use of
speciﬁc phage more than once; II) the rate of clearance
of phages in the body is very high; III) typically, the
intracellular pathogens do not have access to the phage,
and the transport of phages inside intracellular pathogens
requires a delivery system such as non-virulent mycobac-
teria (M. smegmatis) or liposomes. Finally, it is suggested
dedicating a greater body of in vivo and in vitro research
to demonstrate the exact role and efﬁciency of phage
therapy in the treatment of mycobacterial infection, parti-
cularly TB.
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